TQB3306
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2026
TQB3306: a second-generation menin-MLL inhibitor overcoming acquired MEN1 resistance with superior efficacy in acute leukemia models
(EORTC-NCI-AACR 2026)
- "Abstract will be available as of 4 November (with consent of the author)"
Clinical • Hematological Malignancies • Leukemia • Oncology
1 to 1
Of
1
Go to page
1